| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A comparison of the efficacy of trastuzumab deruxtecan in advanced HER2-positive breast cancer: active brain metastasis versus progressive extracranial disease alone
|
Pearson, J.
|
|
|
8 |
6 |
p.
|
artikel
|
| 2 |
Antiplatelet drugs may increase the risk for checkpoint inhibitor-related pneumonitis in advanced cancer patients
|
Araki, T.
|
|
|
8 |
6 |
p.
|
artikel
|
| 3 |
Avelumab first-line maintenance treatment for advanced urothelial carcinoma: review of evidence to guide clinical practice
|
Grivas, P.
|
|
|
8 |
6 |
p.
|
artikel
|
| 4 |
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study ☆
|
Westphalen, C.B.
|
|
|
8 |
6 |
p.
|
artikel
|
| 5 |
Bevacizumab mitigates codon-specific effects of trifluridine/tipiracil on efficacy outcome parameters in metastatic colorectal cancer
|
Doleschal, B.
|
|
|
8 |
6 |
p.
|
artikel
|
| 6 |
Bridging the gap: addressing disparities of access to oncology clinical trials in the geriatric population
|
Rached, L.
|
|
|
8 |
6 |
p.
|
artikel
|
| 7 |
Chemotherapy after nivolumab for advanced gastric cancer (REVIVE): a prospective observational study
|
Narita, Y.
|
|
|
8 |
6 |
p.
|
artikel
|
| 8 |
Chronic fatigue in childhood cancer survivors is associated with lifestyle and psychosocial factors; a DCCSS LATER study
|
Penson, A.
|
|
|
8 |
6 |
p.
|
artikel
|
| 9 |
Circulating pre-treatment T-cell receptor repertoire as a predictive biomarker in advanced or metastatic non-small-cell lung cancer patients treated with pembrolizumab alone or in combination with chemotherapy
|
Abed, A.
|
|
|
8 |
6 |
p.
|
artikel
|
| 10 |
Clinical relevance of gene mutations and rearrangements in advanced differentiated thyroid cancer
|
Nannini, M.
|
|
|
8 |
6 |
p.
|
artikel
|
| 11 |
Comparison of clinical safety between standard versus extended interval dosing of immune checkpoint inhibitors: a real-world retrospective cohort study
|
Colard-Thomas, J.
|
|
|
8 |
6 |
p.
|
artikel
|
| 12 |
Confirmatory validation analysis of the PROFFIT questionnaire to assess financial toxicity in cancer patients
|
Arenare, L.
|
|
|
8 |
6 |
p.
|
artikel
|
| 13 |
Corrigendum to “Authors’ reply—Does the RAPIDO trial suggest a benefit of post-operative chemotherapy after preoperative chemoradiation in rectal cancer? No, it does not”
|
Zwart, W.H.
|
|
|
8 |
6 |
p.
|
artikel
|
| 14 |
Corrigendum to “71P Single nucleotide polymorphisms in the folate metabolic pathway genes and global DNA methylation in ovarian cancer”
|
Surmava, S.
|
|
|
8 |
6 |
p.
|
artikel
|
| 15 |
Corrigendum to “71P Single nucleotide polymorphisms in the folate metabolic pathway genes and global DNA methylation in ovarian cancer”
|
Surmava, S.
|
|
|
8 |
6 |
p.
|
artikel
|
| 16 |
Dacomitinib in EGFR-mutant non-small-cell lung cancer with brain metastasis: a single-arm, phase II study
|
Jung, H.A.
|
|
|
8 |
6 |
p.
|
artikel
|
| 17 |
Defining oligometastatic pancreatic cancer: a systematic review and critical synthesis of consensus
|
Leonhardt, C.-S.
|
|
|
8 |
6 |
p.
|
artikel
|
| 18 |
Diabetes management in cancer patients. An Italian Association of Medical Oncology, Italian Association of Medical Diabetologists, Italian Society of Diabetology, Italian Society of Endocrinology and Italian Society of Pharmacology multidisciplinary consensus position paper
|
Silvestris, N.
|
|
|
8 |
6 |
p.
|
artikel
|
| 19 |
Discontinuation rate and serious adverse events of chemoimmunotherapy as neoadjuvant treatment for triple-negative breast cancer: a systematic review and meta-analysis
|
Rizzo, A.
|
|
|
8 |
6 |
p.
|
artikel
|
| 20 |
Editorial Board
|
|
|
|
8 |
6 |
p.
|
artikel
|
| 21 |
Efficacy of avelumab plus axitinib versus sunitinib by numbers of IMDC risk factors and target tumor sites at baseline in advanced renal cell carcinoma: long-term follow-up results from JAVELIN Renal 101
|
Tomita, Y.
|
|
|
8 |
6 |
p.
|
artikel
|
| 22 |
Efficacy of immune checkpoint inhibitors in alveolar soft-part sarcoma: results from a retrospective worldwide registry
|
Hindi, N.
|
|
|
8 |
6 |
p.
|
artikel
|
| 23 |
Efficacy of olaparib in advanced cancers with germline or somatic mutations in BRCA1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study
|
Joris, S.
|
|
|
8 |
6 |
p.
|
artikel
|
| 24 |
ESMO/ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2023
|
Cufer, Tanja
|
|
|
8 |
6 |
p.
|
artikel
|
| 25 |
ESMO Open: from Cancer Horizons to Science for Optimal Cancer Care—a tale stretching over 8 years
|
Zielinski, C.
|
|
|
8 |
6 |
p.
|
artikel
|
| 26 |
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I study
|
Phadnis, S.
|
|
|
8 |
6 |
p.
|
artikel
|
| 27 |
Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma
|
Lamarca, A.
|
|
|
8 |
6 |
p.
|
artikel
|
| 28 |
Guidelines for the diagnosis and treatment of basal cell carcinoma: a GRADE approach for evidence evaluation and recommendations by the Italian Association of Medical Oncology
|
Queirolo, P.
|
|
|
8 |
6 |
p.
|
artikel
|
| 29 |
Insomnia in adult patients with cancer: ESMO Clinical Practice Guideline ☆
|
Grassi, L.
|
|
|
8 |
6 |
p.
|
artikel
|
| 30 |
In the literature: September 2023
|
Lamarca, A.
|
|
|
8 |
6 |
p.
|
artikel
|
| 31 |
Longitudinal assessment of plasma androgen receptor copy number predicts overall survival in subsequent treatment lines in castration-resistant prostate cancer: analysis from a prospective trial
|
Brighi, N.
|
|
|
8 |
6 |
p.
|
artikel
|
| 32 |
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAFV600-mutated melanoma
|
Blay, J.Y.
|
|
|
8 |
6 |
p.
|
artikel
|
| 33 |
Molecular profiling and feasibility using a comprehensive hybrid capture panel on a consecutive series of non-small-cell lung cancer patients from a single centre
|
Mosteiro, M.
|
|
|
8 |
6 |
p.
|
artikel
|
| 34 |
Multidisciplinary clinical guidelines in proactive monitoring, early diagnosis, and effective management of trastuzumab deruxtecan (T-DXd)-induced interstitial lung disease (ILD) in breast cancer patients
|
Wekking, D.
|
|
|
8 |
6 |
p.
|
artikel
|
| 35 |
Neoadjuvant nivolumab plus chemotherapy versus chemotherapy for resectable NSCLC: subpopulation analysis of Chinese patients in CheckMate 816
|
Wang, C.
|
|
|
8 |
6 |
p.
|
artikel
|
| 36 |
Nivolumab plus chemotherapy in first-line metastatic non-small-cell lung cancer: results of the phase III CheckMate 227 Part 2 trial
|
Borghaei, H.
|
|
|
8 |
6 |
p.
|
artikel
|
| 37 |
On finding acceptance
|
Chen, D.
|
|
|
8 |
6 |
p.
|
artikel
|
| 38 |
Penpulimab combined with anlotinib in patients with R/M HNSCC after failure of platinum-based chemotherapy: a single-arm, multicenter, phase Ⅱ study
|
Shi, Y.
|
|
|
8 |
6 |
p.
|
artikel
|
| 39 |
Prognosticators of survival in patients with metastatic pancreatic cancer and ascites
|
Berger, J.M.
|
|
|
8 |
6 |
p.
|
artikel
|
| 40 |
Response to the letter entitled ‘On finding acceptance’
|
Lim, K.H.J.
|
|
|
8 |
6 |
p.
|
artikel
|
| 41 |
Risk profiles and incidence of cardiovascular events across different cancer types
|
Mitchell, J.D.
|
|
|
8 |
6 |
p.
|
artikel
|
| 42 |
Safety of pregnancy after breast cancer in young women with hormone receptor-positive disease: a systematic review and meta-analysis
|
Arecco, L.
|
|
|
8 |
6 |
p.
|
artikel
|
| 43 |
Sequencing paired tumor DNA and white blood cells improves circulating tumor DNA tracking and detects pathogenic germline variants in localized colon cancer ☆
|
Gimeno-Valiente, F.
|
|
|
8 |
6 |
p.
|
artikel
|
| 44 |
Surgery and HIPEC in relapse for all patients with ovarian cancer?
|
Hasson, S.P.
|
|
|
8 |
6 |
p.
|
artikel
|
| 45 |
Table of Contents
|
|
|
|
8 |
6 |
p.
|
artikel
|
| 46 |
The association of clinical and patient factors with chemotherapy-induced peripheral neuropathy (CIPN) in colorectal cancer: secondary analysis of the SCOT trial
|
Lemanska, A.
|
|
|
8 |
6 |
p.
|
artikel
|
| 47 |
Time toxicity associated with early phase clinical trial participation
|
Nindra, U.
|
|
|
8 |
6 |
p.
|
artikel
|
| 48 |
Validation of the ALK-Brain Prognostic Index for patients with ALK-rearranged lung cancer and brain metastases
|
Zerdes, I.
|
|
|
8 |
6 |
p.
|
artikel
|
| 49 |
What we should focus on and reach out to
|
Nishimura, T.
|
|
|
8 |
6 |
p.
|
artikel
|
Tijdschrift beschrijving